GHRH Analog · Egrifta Is FDA-Approved · Protocol Guide
Tesamorelin Dosage, Side Effects and Results
No marketing hype. No protocol myths. What the clinical evidence actually says about tesamorelin, the only GHRH analog with Phase III data, and how our 2 mg protocol uses it.
- FDA Status
- Egrifta approved 2010; compounded vial is not
- Pharmacy
- Licensed U.S. 503A compounding pharmacy
- Medical Service
- Rx Peps Direct, clinician-supervised
- Access
- 28 States + DC
Our promise: This guide tells you what tesamorelin cannot do as clearly as what it can. We include non-response rates, reversibility data, and side effect frequencies that other sources skip. If a claim is not backed by clinical evidence, we say so.
On this page
Section 01
What Tesamorelin Actually Is
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). It binds to GHRH receptors in the pituitary gland and triggers the natural, pulsatile release of growth hormone. It does not inject GH directly. That matters because pulsatile release preserves your body's feedback mechanisms, unlike exogenous HGH which bypasses them entirely.
Tesamorelin was FDA-approved in November 2010 under the brand name Egrifta (NDA 22-505) for one specific indication: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. That Phase III clinical program produced some of the most robust visceral fat reduction data available for any peptide, including a 15 to 18 percent reduction in visceral adipose tissue (VAT) after 26 weeks at 2 mg per day.
15 to 18%
Visceral fat reduction at 26 weeks in Phase III trials
44
Amino acids in the tesamorelin molecule
2010
FDA approval year. 15+ years of human safety data
Section 02
Who It Is Actually For
Off-label, tesamorelin is used across four consumer profiles with meaningfully different goals. Understanding which profile fits you determines whether tesamorelin is the right choice, and what realistic success looks like for you.
| Profile | Primary Goal | Fit |
|---|---|---|
| Metabolic Optimizer (Male, 35 to 55, often on TRT) | Visceral fat reduction, body recomposition | Excellent |
| Anti-Aging Biohacker (Mixed gender, 45 to 65) | Longevity protocol, skin quality, sleep improvement, injury recovery | Strong |
| Performance Athlete (Male, 25 to 40, bodybuilding focus) | Fat loss during cut, lean mass preservation | Moderate |
| Aesthetic-Only Goals (Primary goal is visible belly fat) | External subcutaneous fat reduction | Poor Fit |
Profile
Primary Goal
Fit
Profile
Primary Goal
Fit
Profile
Primary Goal
Fit
Profile
Primary Goal
Fit
For Women
Tesamorelin for Women
Women can take tesamorelin, but most of the research was done in men. In the two pivotal Egrifta trials, which cut deep belly (visceral) fat by about 15 percent over 26 weeks, roughly 14 to 16 percent of participants were women (Falutz et al., 2010). The most useful trial for women outside HIV gave tesamorelin for 12 months to 60 adults with abdominal obesity, 21 of them women. Visceral fat fell compared with placebo, and the researchers found no difference in effect by sex (Makimura et al., 2012).
| Question | For women |
|---|---|
| Can women take it? | Yes, after a medical review. The approved use is belly fat in adults with HIV-related lipodystrophy; other use is off-label. |
| Dosage for women | The same protocol as for men. There is no separate women's dose in the trials, and your provider sets yours. |
| Before and after | Expect a smaller waist rather than a lower scale weight. Trials measured deep belly fat on scans; fat under the skin changed little. |
| Pregnancy | Contraindicated. The label says it offers no benefit in pregnancy and could harm a fetus. Stop it if you are pregnant or trying to conceive. |
Question
For women
Question
For women
Question
For women
Question
For women
For Men
Tesamorelin for Men: Belly Fat and Visceral Fat
Most of what is known about tesamorelin comes from men. In its first large trial, 86 percent of the 412 participants were men. Deep belly (visceral) fat fell 15.2 percent over 26 weeks on tesamorelin and rose 5.0 percent on placebo, and triglycerides improved (Falutz et al., 2007). The participants had HIV-related belly fat, so use for other belly fat is off-label.
| Question | For men |
|---|---|
| Best peptide for visceral fat? | Tesamorelin is the growth hormone peptide with the strongest visceral fat trials. It targets deep belly fat, not appetite or scale weight. |
| Does it raise testosterone? | No. It works on growth hormone, which is a separate system. |
| With a GLP-1 | They work differently, so some men use both. Your provider decides whether one or both fit you. |
| Tested athletes | Growth hormone peptides are on the WADA prohibited list. If you are drug tested, do not use it. |
Question
For men
Question
For men
Question
For men
Question
For men
More for men: peptides for men over 50, peptides for muscle growth and the full peptides for men guide.
Section 03
How It Works
Tesamorelin binds to GHRH receptors in the anterior pituitary gland and stimulates the natural, pulsatile release of growth hormone. GH then triggers the liver to produce insulin-like growth factor-1 (IGF-1), which drives the downstream metabolic effects, most notably lipolysis (fat breakdown) in visceral adipose tissue.
The mechanism differs critically from exogenous HGH. Because tesamorelin stimulates your own pituitary to release GH naturally, the release remains pulsatile and feedback-regulated. Your body's somatostatin system still applies the brakes. That is why tesamorelin's side effect profile is significantly more favorable than synthetic HGH, and why growth hormone levels typically stay within physiological ranges rather than spiking to supraphysiological levels.
Section 04
Tesamorelin Results: Realistic Expectations
This is the section most guides skip. The community's biggest frustration with tesamorelin is calibration failure: expecting results in 4 weeks when the molecule requires 3 to 6 months. We are going to set the record straight.
The Timeline That Actually Matches Clinical Data
Weeks 1 to 2: Early Adaptation
Deeper sleep and easier mornings are the most common early changes. There is no measurable fat change yet. Any vendor claiming visible results in 1 to 2 weeks is overstating the evidence.
Weeks 8 to 12: Earliest Waist Change
This is the earliest point where waist size starts to change, in people who respond. Measure your waist at your belly button at week 12 and compare it with the number you took before your first dose.
Week 26: The Result Window
The Phase III trial measured its result at 26 weeks: a 15 percent drop in visceral fat on 2 mg a day, holding at 18 percent through 52 weeks for people who kept taking it. Not everyone responds; the trials counted a response as at least an 8 percent drop. If your waist has not changed by week 26, your prescriber will talk with you about stopping.
After 12 Months: The Maintenance Question
Stopping lets visceral fat return. Your prescriber decides with you whether to continue.
Section 05
Tesamorelin Dosage Chart
The Egrifta label and the Phase III trials used 2 mg under the skin once a day. The dose is not weight-based: the trials used one fixed dose for everyone. We offer three doses, five days a week: that same 2 mg and about 1 mg, both drawn from a high-strength vial, and 0.75 mg, drawn from a lower-strength vial. You choose when you order, and your prescriber reviews it. Weight-adjusted dosing calculators you see online have no clinical basis.
| Context | Dose | Timing | Evidence Basis |
|---|---|---|---|
| Egrifta label and Phase III trials | 2 mg per day | Once daily, seven days a week, any time | Phase III RCT |
| Rx Peps Direct, 2 mg | 2 mg (25 units, 0.25 mL of the 8 mg/mL vial), two vials per fill | Once at bedtime, Monday to Friday | Phase III Dose |
| Rx Peps Direct, about 1 mg | About 1 mg (13 units, 0.13 mL of the 8 mg/mL vial), one vial per fill. Your prescriber can also set it as 33 units of the 3 mg/mL vial; the label states the units for the vial you have | Once at bedtime, Monday to Friday | No Visceral Fat Data |
| Rx Peps Direct, 0.75 mg | 0.75 mg (25 units, 0.25 mL of the 3 mg/mL vial), one vial per fill. None of the trials cited here used this dose | Once at bedtime, Monday to Friday | No Visceral Fat Data |
| Titration or ramp-up | None. You can start on any of the three doses. | Not used by the label or the trials | Label and Trials |
| Weight-Based Calculators | Variable formulas | Various | No Clinical Basis |
Context
Dose
Timing
Evidence Basis
Context
Dose
Timing
Evidence Basis
Context
Dose
Timing
Evidence Basis
Context
Dose
Timing
Evidence Basis
Context
Dose
Timing
Evidence Basis
Context
Dose
Timing
Evidence Basis
Tesamorelin dosage per day and per week, in syringe units
One injection a day, Monday to Friday, so a week is five doses. Units are on a U-100 insulin syringe. Read the strength on your vial's label first: the same unit mark gives a different dose on each vial.
| Dose per day | Vial | Draw | Per week | Doses per vial |
|---|---|---|---|---|
| 2 mg | 8 mg/mL | 25 units (0.25 mL) | 10 mg | 12 |
| About 1 mg (1.04 mg) | 8 mg/mL | 13 units (0.13 mL) | 5.2 mg | 23 |
| About 1 mg (0.99 mg) | 3 mg/mL | 33 units (0.33 mL) | About 5 mg | 15 |
| 0.75 mg | 3 mg/mL | 25 units (0.25 mL) | 3.75 mg | 20 |
Dose per day
Vial
Draw
Per week
Doses per vial
Dose per day
Vial
Draw
Per week
Doses per vial
Dose per day
Vial
Draw
Per week
Doses per vial
Dose per day
Vial
Draw
Per week
Doses per vial
To convert any tesamorelin dose to syringe units for a vial you already have, use the tesamorelin dosage calculator. It does the units math only; your prescriber sets the dose.
2 mg, 8 mg/mL Vial
Draw to the 25-unit mark on a U-100 insulin syringe, 0.3 mL barrel
25 units = 0.25 mL = 2 mg
Once at bedtime, Monday to Friday, under the skin of the abdomen. This is the dose the Phase III visceral fat results came from. One 24 mg vial holds 12 doses, and a fill is two vials.
About 1 mg, 8 mg/mL Vial
Draw to the 13-unit mark on a U-100 insulin syringe, 0.3 mL barrel
13 units = 0.13 mL = 1.04 mg
Once at bedtime, Monday to Friday. One 24 mg vial holds 23 doses, and a fill is one vial. The trials did not measure visceral fat at this dose, so expect less. Your prescriber can also lower a 2 mg dose to this: for a two-week tolerance start, for joint pain, swelling, numbness or tingling in the hands, or rising home glucose readings, or for older or smaller patients and those with diabetes. If your prescriber sets it on the 3 mg/mL vial instead, it is 33 units (0.33 mL). The label states the units for the vial you have.
0.75 mg, 3 mg/mL Vial
Draw to the 25-unit mark on a U-100 insulin syringe, 0.3 mL barrel
25 units = 0.25 mL = 0.75 mg
Once at bedtime, Monday to Friday. One 15 mg vial holds 20 doses, and a fill is one vial, which lasts 4 weeks. None of the trials cited here used this dose, and none measured visceral fat below 2 mg. It is the same 25-unit draw as 2 mg, on a different vial, so check the label before every draw.
Why We Run It This Way
- 2 mg is the dose the visceral fat results came from. The Phase III trials reported a 15 to 18 percent drop in visceral fat at 26 weeks on 2 mg a day. That is the dose to use when visceral fat is the goal.
- Why five days a week, not seven. The pharmacy sends at most two vials per fill. Two vials hold 24 doses. On a five-day week that lasts almost five weeks; on a seven-day week it would run out in 24 days. Five days a week gives you about 71 percent of the trial's weekly amount, so results may be smaller in proportion.
- Two strengths, and the same unit mark is a different dose on each. Tesamorelin comes as an 8 mg/mL vial and a 3 mg/mL vial. That is why the label check above comes before every draw.
- Why no routine ramp-up. Neither the approved label nor the trials titrate, so there is no dose you have to pass through first: you can start on any of them. Your prescriber can lower the dose, for example for a two-week start to check tolerance.
- Why bedtime. It lines up with the natural growth hormone pulse during deep sleep. The trials allowed any time of day, so consistency matters more than the exact hour.
- How long. At least 26 weeks, then your prescriber reviews whether to continue.
Injection Site Guidance
Inject under the skin of the abdomen. Rotate injection sites within the abdomen to avoid scar tissue buildup. Avoid the 2-inch zone around the navel. Use a U-100 insulin syringe. A 0.3 mL (30-unit) barrel reads a draw of up to 30 units most accurately; a 33-unit draw is more than that barrel holds and needs a larger one. Take the vial out of the refrigerator 5 to 10 minutes before drawing to reduce discomfort.
Section 06
Cycling: What the Evidence Says
The cycling debate is one of the most contentious, misinformation-heavy topics in the tesamorelin community. Here is what is actually known versus community mythology.
| Claim | Source | Evidence Level |
|---|---|---|
| Must cycle to prevent GH desensitization | Forum extrapolation | Theoretical |
| Continuous use up to 52 weeks is documented | Phase III safety extension | Phase III Data |
| 5-on / 2-off is sufficient cycling | Community consensus | No Direct Evidence |
| Visceral fat reaccumulates within 12 weeks of stopping | Phase III follow-up | Documented |
Claim
Source
Evidence Level
Claim
Source
Evidence Level
Claim
Source
Evidence Level
Claim
Source
Evidence Level
Tesamorelin Side Effects and How to Manage Them
Tesamorelin has the most thoroughly characterized side effect profile of any peptide Rx Peps Direct prescribes: 15 years of Phase III and post-approval data from the Egrifta program. The side effects below are drawn from the Phase III trials (n=543 in LIPO-010A and LIPO-010B) and the 52-week safety extension study, not from community inference.
| Side Effect | Frequency | When | Mitigation |
|---|---|---|---|
| Injection site reaction (redness, swelling, pruritus) | Common (25-30%) | First 4 to 8 weeks | Rotate sites across the abdomen. The pharmacy ships pre-reconstituted: no reconstitution variability. Typically diminishes by week 8. Message your provider if redness keeps spreading. |
| Peripheral edema (swelling in the hands or feet) | Common (15-20%) | First 4 to 8 weeks | Message your provider. This usually means your prescriber lowers the dose, not that the drug stops. Do not add diuretics without your prescriber's approval. |
| Arthralgia (joint pain, commonly hands and wrists) | Common (12-18%) | Weeks 2 to 12 | Message your provider. The usual step is your prescriber lowering the dose. Resolves on discontinuation in most patients. |
| Glucose elevation (growth hormone lowers insulin sensitivity) | Common (10-15%) | Ongoing | If you have diabetes or prediabetes, send a recent HbA1c or fasting glucose from your own doctor before your first fill. Report rising home glucose readings, increased thirst, or frequent urination; your prescriber may lower the dose. Keep the doctor who manages your diabetes informed. |
| Carpal tunnel symptoms (tingling or numbness in the hands) | Uncommon (8-10%) | Weeks 4 to 12 | Dose-dependent. Message your provider; the dose usually comes down. Resolves on discontinuation in most cases. |
| Nausea | Uncommon (5-8%) | First 2 to 4 weeks | Evening injection minimizes daytime nausea. Self-limiting in most patients. |
Side Effect
Frequency
When
Mitigation
Side Effect
Frequency
When
Mitigation
Side Effect
Frequency
When
Mitigation
Side Effect
Frequency
When
Mitigation
Side Effect
Frequency
When
Mitigation
Side Effect
Frequency
When
Mitigation
Section 07
Ready to Inject
0
Reconstitution steps required
503A
Licensed 503A pharmacy, clinician-supervised
Overnight
FedEx shipping in a reusable cooled travel case
Storage
Keep vials in the refrigerator at 36 to 46 degrees F (2 to 8 degrees C), away from light, and never frozen. Follow the Beyond Use Date printed on the label, which the pharmacy sets under USP <797> sterile compounding standards.
Section 08
Tracking Your Response
Visceral fat sits deep around your organs, so the mirror is a poor guide. The simplest honest measure is your waist. Measure it at your belly button before your first dose, at week 12, and at week 26. That measurement, along with how you feel and how you tolerate the dose, is how you and your prescriber judge whether tesamorelin is working.
What to Track at Home
| What | When | How | What to Tell Your Prescriber |
|---|---|---|---|
| Waist at your belly button | Before your first dose, week 12, week 26 | Tape measure, standing, same time of day each time | Your three numbers. No change by week 26 means a conversation about stopping. |
| Sleep and how you feel | A quick weekly note | Phone note | Anything that changes, good or bad |
| Joint pain, swelling in hands or feet, hand tingling or numbness | Whenever it shows up | Phone note (0 to 10 severity) | Message your provider. The dose usually comes down, and your prescriber can lower it. |
| Home glucose readings, if you check them | Whenever they start rising | Your own meter | Message your provider. Rising readings are a reason your prescriber may lower the dose. |
| Injection site | Each injection | Look at the site | Redness spreading beyond 2 cm, warmth, or a lump: message your provider |
What
When
How
What to Tell Your Prescriber
What
When
How
What to Tell Your Prescriber
What
When
How
What to Tell Your Prescriber
What
When
How
What to Tell Your Prescriber
What
When
How
What to Tell Your Prescriber
Section 09
Stacking
Tesamorelin pairs well with non-GH-axis compounds and with TRT for men over 45. Stacking with other GH-axis compounds (HGH, MK-677) increases unpredictability without proportional benefit.
Pairs Well With
Ipamorelin
Different receptor (ghrelin) means complementary, not redundant, GH stimulation. Available as combo (Tesamorelin / Ipamorelin).
BPC-157
Tissue repair and gut healing. Complementary mechanism, no known interaction.
Optimized TRT
Tesamorelin layered onto established testosterone therapy is one of the highest-fit applications for men 45 plus targeting visceral fat.
MOTS-c
Mitochondrial peptide. Targets metabolic function via a different pathway.
Approach With Caution
Exogenous HGH
Combining GH secretagogue with exogenous GH causes supraphysiologic GH levels. Clinician assessment required.
MK-677 (Ibutamoren)
Oral GH secretagogue. Can cause sustained GH elevation and insulin resistance when stacked.
Glucocorticoids
Suppress GH response. May blunt the growth hormone response to tesamorelin.
AOD-9604
Targets visceral and subcutaneous fat with a different mechanism. Overlap with tesamorelin produces unclear stacking benefit.
Section 10
Pricing
What a Course Costs
| What | 0.75 mg (25 Units) | About 1 mg (13 Units) | 2 mg (25 Units) | About 1 mg, 3 mg/mL Vial (33 Units). Prescriber Only |
|---|---|---|---|---|
| Vial | 15 mg, 3 mg/mL | 24 mg, 8 mg/mL | 24 mg, 8 mg/mL | 15 mg, 3 mg/mL |
| Doses per vial | 20 | 23 | 12 | 15 |
| Vials per fill | 1 | 1 | 2 | 1 |
| Pharmacy cost per fill | $100 | $200 | $400 | $100 |
| One fill lasts | 4 weeks (20 doses) | About 4.6 weeks (23 doses) | About 4.8 weeks (24 doses) | 3 weeks (15 doses) |
| Cost per week | $25 | About $43 | About $83 | About $33 |
| 26-week course (pharmacy) | 7 vials, $700 | 6 vials, $1,200 | 11 vials, $2,200 | 9 vials, $900 |
What
0.75 mg (25 Units)
About 1 mg (13 Units)
2 mg (25 Units)
About 1 mg, 3 mg/mL Vial (33 Units). Prescriber Only
What
0.75 mg (25 Units)
About 1 mg (13 Units)
2 mg (25 Units)
About 1 mg, 3 mg/mL Vial (33 Units). Prescriber Only
What
0.75 mg (25 Units)
About 1 mg (13 Units)
2 mg (25 Units)
About 1 mg, 3 mg/mL Vial (33 Units). Prescriber Only
What
0.75 mg (25 Units)
About 1 mg (13 Units)
2 mg (25 Units)
About 1 mg, 3 mg/mL Vial (33 Units). Prescriber Only
What
0.75 mg (25 Units)
About 1 mg (13 Units)
2 mg (25 Units)
About 1 mg, 3 mg/mL Vial (33 Units). Prescriber Only
What
0.75 mg (25 Units)
About 1 mg (13 Units)
2 mg (25 Units)
About 1 mg, 3 mg/mL Vial (33 Units). Prescriber Only
What
0.75 mg (25 Units)
About 1 mg (13 Units)
2 mg (25 Units)
About 1 mg, 3 mg/mL Vial (33 Units). Prescriber Only
The 33-unit dose on the 3 mg/mL vial is set by your prescriber only, and the label states the units for the vial you have. Each order also carries the $39 prescriber review. Pharmacy prices are the pharmacy's own; we add nothing to them.
| Option | Medication Cost | Medical Cost | Notes |
|---|---|---|---|
| Brand-Name Egrifta (specialty pharmacy) | $3,000 to $6,000 per month range | Insurance and prescriber dependent | Branded finished form for HIV-associated lipodystrophy. Out-of-pocket cost without insurance is prohibitive for most off-label users. |
| Other Online Clinics | $300 to $500 per month | Visit fees often bundled and not disclosed publicly | Per-cycle pricing varies. Verify all-in cost before committing. |
| Rx Peps Direct + licensed 503A pharmacy | $200 per 24 mg vial, paid to pharmacy (1 vial a fill at about 1 mg, 2 vials at 2 mg); $100 per 15 mg vial at 0.75 mg | $39 prescriber review per order, paid to Rx Peps Direct | Pre-reconstituted, FedEx overnight. |
Option
Medication Cost
Medical Cost
Notes
Option
Medication Cost
Medical Cost
Notes
Option
Medication Cost
Medical Cost
Notes
Who You Pay, and What For
Pharmacy: Medication
$200 per 24 mg vial. A fill is one vial at about 1 mg, or two vials ($400) at 2 mg. At 0.75 mg a fill is one 15 mg vial ($100). Compounded and shipped by a licensed U.S. 503A compounding pharmacy. Pre-reconstituted, FedEx overnight in a reusable cooled travel case.
Medical Service: Prescriber Review
$39 prescriber review per order. Intake review, protocol, prescription writing, and follow-up messages in the patient portal. Billed by Rx Peps Direct for the medical service only.
Section 11
Legal Access in 28 States + DC
FDA-Approved Finished Form
Egrifta, branded by Theratechnologies
Compounded, Not an Approved Product
The compounded vial is not Egrifta and is not FDA approved
Off-Label Use of an Approved Molecule
Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy; this compounded vial is a different product
Regulated as a Biological Product
Egrifta moved from NDA to BLA 022505 on 3/23/2020 under the BPCI Act
Tesamorelin has an FDA-approved finished form, Egrifta, for HIV-associated lipodystrophy. Its regulatory status changed on March 23, 2020: under the BPCI Act transition, tesamorelin is a 44-amino-acid polypeptide, above the 40-amino-acid line the FDA uses to separate drugs from biological products, so Egrifta was deemed a licensed biological product (BLA 022505) rather than an approved drug. That distinction matters for how a compounded preparation is treated, and it is a question to raise with your prescriber and the pharmacy that fills it.
Off-label prescribing is a standard, legal practice in U.S. medicine. Your prescriber will explain the regulatory status and evidence base for your specific protocol during your consultation.
Section 12
Community Q&A
Will tesamorelin shrink the belly fat I can see in the mirror?
Tesamorelin reduces visceral fat, the deep abdominal fat around your organs, not subcutaneous fat, the fat you can pinch. The visible mirror change is often subtle even when the metabolic benefit is significant. If your goal is purely aesthetic, you may not see a dramatic change.
How long until I see results?
Most people notice deeper sleep in the first two weeks, with no fat change yet. The earliest change in waist size shows up between weeks 8 and 12 in people who respond. The Phase III trials measured their result at 26 weeks, so plan on at least 26 weeks of doses taken as prescribed, then a review with your prescriber.
What happens when I stop?
Clinical data confirms visceral fat reaccumulates within approximately 12 weeks of discontinuation. Tesamorelin is a maintenance therapy. Plan accordingly.
Is tesamorelin safe long-term?
The Egrifta program documented continuous use up to 52 weeks without loss of effect or new safety signals. Glucose elevation is the most commonly reported lab finding in the trials, so tell your Rx Peps Direct prescriber about diabetes or prediabetes before you start. If you have either, send a recent HbA1c or fasting glucose from your own doctor before your first fill, and keep your own doctor involved.
What if my waist has not changed?
Give it time: the earliest waist change shows up between weeks 8 and 12, and the trials measured their result at week 26. Roughly 31 percent of Phase III participants did not reach the primary endpoint, so some people are non-responders even when they take every dose. If your waist has not changed by week 26, your prescriber will talk with you about stopping.
Why five days a week instead of seven?
The pharmacy sends at most two vials per fill, and two vials hold 24 doses at 2 mg. On a five-day week that lasts almost five weeks; on a seven-day week it would run out in 24 days. Five days a week is about 71 percent of the trial's weekly amount, so results may be smaller in proportion.
Can I use tesamorelin with TRT?
Yes. Tesamorelin layered onto established testosterone therapy is one of the highest-fit clinical applications for men 45 plus targeting visceral fat. Your Rx Peps Direct clinician will review your existing TRT protocol at intake.
What happens if the pharmacy is out of stock?
Pharmacy supply chains can fluctuate. If the pharmacy is temporarily unable to fill your prescription, your Rx Peps Direct clinician will be notified and you will be contacted before any delay impacts your protocol. You only pay the pharmacy when your prescription actually ships.
Section 13
The Rx Peps Direct Model
Tesamorelin is the only GHRH analog with Phase III trial data and an FDA-approved brand, Egrifta. Our compounded vial is not FDA approved. The Egrifta program established its safety profile across 52 weeks of continuous use. Within those limits, the visible mirror change is subtle, the non-responder rate is roughly 31 percent, and visceral fat reaccumulates when you stop. Rx Peps Direct clinicians will set realistic expectations based on your history and your starting waist measurement.
Pharmacy: Licensed U.S. 503A
The pharmacy compounds your tesamorelin under a patient-specific prescription, USP <797> sterile standards, and federal 503A oversight. The pharmacy ships the medication directly to you and bills you for the medication.
Medical Service: Rx Peps Direct Clinicians
A licensed clinician reviews your history, designs your protocol, writes your prescription, and reviews your waist measurements and side effects. Rx Peps Direct bills the $39 prescriber review for this service.
Transparent Safety Communication
The guide above flags the 31 percent non-responder rate, the subcutaneous vs visceral fat distinction, the reaccumulation timeline, and the biological-product status of the molecule. We do not hide limitations to make a sale.
Legal Access in 28 States + DC
Every shipment is a compounded prescription medication filled by a 503A licensed pharmacy under a prescription. Tesamorelin has an FDA-approved finished form, Egrifta, which the FDA has regulated as a licensed biological product since March 2020.
References
- Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010. PMID: 20101189
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials. J Clin Endocrinol Metab. 2010. PMID: 20554713
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014. PMID: 25038357
- Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011. PMID: 21668043
Related protocol guides
Other protocols in the same clinical territory. Each guide is co-bylined by a licensed Rx Peps Direct prescriber.
GHRH analog (GRF 1-29)
Sermorelin protocol guide: pharmacology, dosing, tracking your response, and the non-responder reality
The only GHRH analog still Category 1 compoundable. Daily injection, 6 to 12 month protocol, 30 to 40 percent non-responder rate, and IGF-1 the biomarker that decides the answer.
Growth hormone stack
CJC-1295 / Ipamorelin protocol guide: dosing, units-to-mcg, timelines, and the legal pathway
Pulsatility, DAC vs no-DAC, syringe math, the 90-day rule, gray-market purity data, and the 503A pathway. Written for the patient who wants the full picture.
Oral GH secretagogue (MK-677)
Ibutamoren (MK-677) guide: oral ghrelin receptor agonist, water retention, glucose elevation, WADA prohibition
The only oral GH secretagogue. Real GH and IGF-1 elevation. Real water retention. Real fasting-glucose drift. WADA prohibited. Monitoring is mandatory.